News

Meridigen New Stem Cell Drug Continues to Achieve Great Milestones

2020-02-03

Meridigen applied a self-developed human umbilical mesenchymal stem cell drug (UMC119-06) for the treatment of Acute Respiratory Distress Syndrome (ARDS) in Phase I clinical trial. Currently approved by the US Food and Drug Administration (FDA) on January 14, 2020.

According to the statistics, ARDS occurrence was estimated to be 10% in all ICU admissions. The overall hospital mortality was approximately 30%- 50% due to the lack of specific treatment methods for the pathogenesis of ARDS.

In this generation of regenerative medicine, Meridigen will be dedicated to developing and manufacturing mesenchymal stem cells in complying with the international standard of Pharmaceutical Inspection Co-operation Scheme Good Manufacturing Practice, PIC/S GMP. Besides, it works collaboratively with Taipei Medical University-Shuang Ho Hospital to shape the future of regenerative medical treatment mode for ARDS.

Back toNews